Almotriptan: a novel 5-HT1B/D agonist for the symptomatic treatment of migraine

References

• Headache Classification Committee of the International Headache Society. Classification of headache disorders, cranial neuralgias and facial pain. Cephalalgia 8 (Suppl. 7), 1–96 (1988).
   Google Scholar
• Hu XH, Markson LE, Lipton RB, Stewart WE Berger ML. Burden of migraine in the United Sates: disability and economic costs. Arch. Intern. Med. 159(1), 813–818 (1999).
   Google Scholar
• Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET. Serotonin and migraine. Ann. NY Acad. Sci. 600(4), 587–598 (1990).
   Google Scholar
• Goadsby PJ. Serotonin receptors and the acute attack of migraine. Clin. Neurosci. 5(1), 18–23 (1998).
   PubMedGoogle Scholar
• Silberstein SD. Preventive treatment of migraine: an overview. Cepha/a/gia 17(2), 67–73 (1997).
   PubMed Web of Science ®Google Scholar
• Pascual J, Leira R, Lainez JM et al. Estudio espahol de calidad de vida en la migrafia (II). Patron de consumo de farmacos y eficacia subjetiva. Neurologia 14(5), 204–209 (1999).
   PubMedGoogle Scholar
• Tfelt-Hansen P, Saxena PR, Dahlof C et al. Ergotamine in the acute treatment of migraine. A review and European consensus. Brain 123(1), 9–18 (2000).
   PubMed Web of Science ®Google Scholar
• Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs 55(6), 889–922 (1998)
   PubMed Web of Science ®Google Scholar
• Spencer CM, Gunasekara NS, Hills C. Zolmitriptan. A review of its use in migraine. Drugs 58(2), 347–374 (1999).
   Google Scholar
• Mathew NT. Naratriptan: review. Exp. Opin. Invest. Drugs 8(5), 687–695 (1999). itDahlof C, Lines C. Rizatriptan: a new 5- HT1B/1D receptor agonist for the treatment of migraine. Exp. Opin. Invest. Drugs 8(5), 671–685 (1999).
   Google Scholar
• Goadsby PJ, Ferrari MD, Olesen J etal. Eletriptan in acute migraine: a double- blind, placebo-controlled comparison to sumatriptan. Neurology54 (1), 156–163 (2000).
   PubMed Web of Science ®Google Scholar
• Bou J, Domenech T, Puig J, Heredia A et al. Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur. Pharmacol. 410(1), 33–41 (2000).
   Google Scholar
• ••Key pharmacological study withalmotriptan.
   Google Scholar
• Gras J. Functional profile of almotriptan in animals models predictive of antimigraine activity. Eur. I Pharmacol. 410(1), 43–51 (2000).
   PubMed Web of Science ®Google Scholar
• Fernandez FJ, Jansat JM, Cabarrocas X, Costa J, Salva P Absolute bioavailability of oral and sc. almotriptan. Cephalalgia 23(4), 363 (1999).
   Google Scholar
• Garcia E, Cabarrocas X, Jansat JM et al. A clinical trial to determine the lack of food interaction on the bioavailability of almotriptan, a new 5HT1B/1D agonist, in healthy volunteers. Headache 38(5), 381 (1988).
   Google Scholar
• Cabarrocas X, Jansat JM, Ferrer 1', Luria X. Pharmacokinetics of oral almotriptan during and outside a migraine attack. Cephalalgia 19(5), 417 (1999).
   Google Scholar
• Cabarrocas X, Warrington SJ, Jansat JM, Zayas JM, Boyce M, Ferrer P Pharmacokinetics and tolerability of almotriptan in the elderly. Cephalalgia 19(5), 363 (1999).
   Google Scholar
• Cabarrocas X, Fernández FJ, Popescu G, Jansat JM, Molz K, Ferrer P The pharmacokinetics and tolerability of almotriptan in renal impairment. Headache 39(5), 346 (1999)
   Google Scholar
• Fleishaker JC, Ryan KK, Jansat JM et al. Effect of MAO-A inhibition on the pharmacokinetics of the novel antimigraine agent, almotriptan, in humans. Br. J. Pharmacol. Br. J. Clin. Pharmacol. 51(5), 437–441 (2001).
   Google Scholar
• Fleishaker JC. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J. Clin. Pharmacol. 41 (2), 217–223 (2001).
   Google Scholar
• Fleishaker JC, Sisson T, Carel B, Azie N. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan and propranolol in healthy volunteers. Cephalalgia 21(1), 61–65 (2001).
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin. Pharmacol. Ther 67(5), 498–503 (2000).
   Google Scholar
• Pascual J. Therapy with other triptans: almotriptan. In: Monographs in Clinical Neurosciences (volume 17). Drug treatment of migraine and other frequent headaches. Diener HC (Ed.), Karger, Basel, Switzerland, 197–205 (2000).
   Google Scholar
• Pascual J, Penis F, Cabarrocas X, Luria X. Meta-analysis of the efficacy of almotriptan for the treatment of acute migraine attacks. Cephalalgia 21(4), 427 (2001).
   Google Scholar
• Pascual J, Falk RIVI, Piessens F eta]. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomised, double-blind, placebo-controlled study. Cephalalgia 20(6), 588–596 (2000).
   PubMed Web of Science ®Google Scholar
• ••The most important Phase III clinical trialwith almotriptan.
   Google Scholar
• Dowson A, Pascual J, Lainez M et al. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomised, double-blind, placebo-controlled clinical trial. Cephalalgia (In press).
   Google Scholar
• •• The comparative, placebo-controlled clinical trial against sumatriptan 100 mg.
   Google Scholar
• Spierings EL, Górnez-Mancilla B, Gras DE, Rowland CR, Whaley FS, Jirgens KJ. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch. Neurol. 58(6), 944–950 (2001).
   Google Scholar
• Colman SS, Brod MI, Krishnamurthy A, Rowland CR. Jirgens KJ, Górnez-Mancilla B. Treatment satisfaction, functional status and health-related quality of life of migraine patients treated with almotriptan and sumatriptan. Clin. Ther. 23(1), 127–145 (2001).
   Google Scholar
• Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache 41(5), 449–555 (2001).
   PubMed Web of Science ®Google Scholar
• Boyce M, Dunn K, Warrrington S. Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers. Cardiovas. Pharmacol 37(3), 280–289 (2001).
   Google Scholar
• •Safety study showing no major adverse events with almotriptan at high doses in human volunteers.
   Google Scholar
• Gras J, Cardelus I, Llenas J, Palacios JM. Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine. Eur. Pharmacol. 410(1), 53–59 (2000).
   PubMed Web of Science ®Google Scholar
• •A further safety trial analyzing the cardiovascular profile of almotriptan.
   Google Scholar
• Cabarrocas X, Esbri R, Penis F, Ferrer P. Long-term efficacy and safety of oral almotriptan: interim analysis of a 1-year open study. Headache 41(1), 57–62 (2001).
   Google Scholar
• Pascual J, Falk J, Docekal R et al. The tolerability and efficacy of almotriptan in long-term treatment of migraine. Eur. Neurol. 45(4), 206–213 (2001).
   PubMed Web of Science ®Google Scholar
• ••Major long-term, open clinical trialshowing a placebo-like tolerability of almotriptan 12.5 mg.
   Google Scholar
• Pascual J, Cabarrocas X. Within-patient early vs. delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache Submitted.
   Google Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55 (6), 754–762 (2000).
   PubMed Web of Science ®Google Scholar